TRADE NEWS: Agilent Technologies and 10x Genomics Announce Collaboration to Develop a Premium Exome
February 11 2016 - 11:00AM
Business Wire
New Data Type Includes Haplotype Phasing,
Structural Variant Detection, Improved SNP Calling
Agilent Technologies Inc. (NYSE: A) and 10x
Genomics today announced a collaboration to develop a
groundbreaking exome allowing in-depth discovery of important novel
content within and around the exome by enabling phasing, access to
previously unmappable loci, structural variation, and copy number
detection through the use of complementary products of both
companies. The two companies will each create products that provide
a streamlined workflow for 10x Genomics’ Chromium platform using
Agilent’s market-leading SureSelect target enrichment
technology.
The Chromium platform is a unique molecular barcoding and
analysis platform that consists of hardware, reagents and software
to generate a new, single-molecule resolution sequencing data type:
Linked-Reads. Linked-Reads deliver long-range information,
including haplotype phasing, structural variation and other
critical genomic context, from DNA inputs of approximately 1
ng.
Building upon Agilent’s legacy and leadership in target
enrichment, the collaboration entails coupling the 10x Genomics
Linked-Read technology with an optimized Agilent SureSelect target
enrichment solution to deliver coverage and variant calling,
including in hard-to-map regions of the genome. Most important,
this solution will include both exonic targets and additional loci
to enhance phasing, thus providing more insight into complex
genomic structural anomalies, something that is not possible with
target enrichment products on the market today.
“Our collaboration with 10x Genomics will advance the
understanding of underlying causes of disease, and we are excited
to be at the forefront of this innovation,” said Herman Verrelst,
Agilent VP and general manager, Genomics Division, in the
Diagnostics and Genomics Group. “Its unique potential to resolve
maternal and paternal haplotypes and the ability to detect
structural variants, such as translocations, will make a
significant impact on clinical research for constitutional diseases
and cancer.”
“10x Genomics is excited to collaborate with Agilent to bring
the power of long-range information to exome sequencing
applications,” said Serge Saxonov, 10x Genomics’ chief executive
officer. “Optimized Agilent SureSelect panels running with the 10x
Genomics Chromium platform will add significant value to our
customers’ targeted sequencing projects by offering loci in the
genome that were previously difficult to access, as well as
compound heterozygote phasing, structural variation and copy number
detection.”
For more information, please visit 10xgenomics.com and
www.agilent.com.
About 10x Genomics
10x Genomics is changing the definition of sequencing by
providing an innovative genomics platform that dramatically
upgrades the capabilities of existing short read sequencers. The
Company does this through a combination of elegant microfluidics,
chemistry and bioinformatics. With the Chromium System running
GemCode™ technology, researchers can now find structural variants,
haplotypes, and other valuable long range information while
leveraging existing sequencing workflows.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A), a global leader in
life sciences, diagnostics and applied chemical markets, is the
premier laboratory partner for a better world. Agilent works with
customers in more than 100 countries, providing instruments,
software, services and consumables for the entire laboratory
workflow. The company generated revenue of $4.04 billion in fiscal
2015 and employs about 12,000 people worldwide. Information about
Agilent is available at www.agilent.com.
NOTE TO EDITORS: Further technology, corporate citizenship and
executive news is available at www.agilent.com/go/news.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160211005140/en/
Agilent Technologies Inc.Victoria Wadsworth-Hansen, +1
408-553-2005victoria.wadsworth-hansen@agilent.comorChempetitive
Group for 10x GenomicsTrisha Rule, +1
858-230-4949trule@chempetitive.com
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agilent Technologies (NYSE:A)
Historical Stock Chart
From Apr 2023 to Apr 2024